Yes. Integration coaching is legal. Coaches do not facilitate or administer substances. Instead, they provide harm-reduction education, support, and post-experience guidance.

No. As an integration coach, I do not supply, administer, or sit in on psychedelic sessions. I help clients prepare beforehand and integrate the insights afterward.

Yes! Integration coaching works beautifully alongside psychotherapy, somatic therapy, and psychiatric care. It offers a bridge between insight and embodiment—especially after transformative experiences.

If you’re seeking clarity, processing help, or direction after (or before) a psychedelic experience, coaching can provide the structure and support needed to translate inner shifts into life-altering changes.

Absolutely. Challenging or “bad” trips often carry profound lessons when processed properly. Integration coaching offers a safe, non-judgmental space to explore what came up and how to move forward meaningfully.

While both aim to support mental and emotional well-being, therapists diagnose and treat mental health conditions, whereas coaches do not. Coaching is typically future-focused, emphasizing self-awareness, personal growth, and actionable steps, especially concerning psychedelic experiences and spiritual development.

No. Integration coaching can support personal development and emotional healing even if you haven't used psychedelics. The focus is on integrating aspects of yourself and your experiences, regardless of the catalyst.

Psychedelic integration coaching assists individuals in processing and applying insights from psychedelic experiences into their daily lives. This support can enhance personal growth, emotional healing, and spiritual development. Coaching may occur before (preparation) or after (integration) psychedelic experiences, regardless of when they occurred.

Ketamine is a legal, FDA-approved medicine for treatment-resistant depression and chronic pain, with several delivery methods: Intravenous (IV): Fast-acting; typically administered in clinics. (Source: Science Direct) Intramuscular (IM): Injected into the muscle for rapid relief. (Source: PubMed) Oral (Lozenges/Tablets): Often used in at-home ketamine therapy. (Source: PubMed) Nasal Spray (Spravato): FDA-approved esketamine for TRD, administered in-office. (Source: Psychiatrist.com) Subcutaneous (SubQ): Emerging option offered through clinics like Mindbloom. (Source: Mindbloom) Microdosing: Low-dose ketamine, often delivered through programs like Joyous, is gaining interest but requires more study. (Source: Joyous)

Yes—when administered under medical supervision. It’s considered one of the most promising treatments for individuals with treatment-resistant depression. However, careful screening and medical oversight are essential. (Source: Harvard Health)

Ketamine is a Schedule III controlled substance, legal for use in medical settings. It is FDA-approved as an anesthetic and in its esketamine form (Spravato) for treatment-resistant depression.

Microdosing involves taking sub-perceptual doses of psilocybin. Anecdotal reports suggest improvements in mood, creativity, focus, and emotional regulation. Dr. James Fadiman’s work laid the foundation for this modern movement. ​ (Source: Microdosing Institute)

Psilocybin is classified as a Schedule I substance federally, making it illegal under most circumstances. However, Oregon and Colorado have decriminalized and created supervised, licensed psilocybin therapy programs. Other cities (like Oakland and Santa Cruz) have decriminalized it. (Source: Psychedelic Alpha- State Law Tracker)

Microdosing aims to create subtle shifts while maintaining full daily function. Full-dose sessions, in contrast, create immersive experiences that often require emotional preparation, guided support, and longer-term integration. (Source: JAMA Network Study on Psilocybin)

Psilocybin, found in “magic mushrooms,” has shown effectiveness in reducing symptoms of major depression, anxiety, and addiction. Studies suggest that a single guided session can yield lasting relief for many. ​ (Source: Johns Hopkins Medicine)

Some religious groups in the U.S. have applied for legal exemptions to use psilocybin in ceremonial contexts under the Religious Freedom Restoration Act (RFRA), but legal recognition is rare and complex. (Source: Cato Institute)